Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
National Cancer Institute (NCI)
AstraZeneca
Genmab
Daiichi Sankyo
BioNTech SE
Gustave Roussy, Cancer Campus, Grand Paris
UNICANCER
Hutchmed
University of Virginia
Charles University, Czech Republic